BSX Stock Recent News
BSX LATEST HEADLINES
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment and continued geographical expansion.
Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker MARLBOROUGH, Mass. , May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP).
Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.
We have narrowed our search to five U.S. corporate behemoths that have strong growth potential for 2024. These are: GOOGL, NFLX, AMZN, NOW, BSX.
Many Wall Street investors keep a close eye on the opinions of major brokerages, such as Citigroup (NYSE: C ). Therefore, today we'll explore three promising growth stocks that have recently received a vote of confidence by means of increases in Citi price targets.
It's not exactly an ideal time to be a stock market investor. The market is in correction territory, with many leading tech giants experiencing a pullback in prices.
Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.